{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:11:14Z","timestamp":1773015074083,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41415-020-1365-5","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T12:02:58Z","timestamp":1585310578000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Deciphering novel chemotherapy and its impact on dentistry"],"prefix":"10.1038","volume":"228","author":[{"given":"Rebecca","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Zebic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"key":"1365_CR21361","doi-asserted-by":"crossref","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci 2017; 18: 1-25.","DOI":"10.3390\/ijms18071414"},{"key":"1365_CR21363","unstructured":"Di Martino S, Rainone A, Troise A et al. Overview of FDA-Approved Anti Cancer Drugs Used for Targeted Therapy. World Cancer Res J 2015; 2: e553. Available online at https:\/\/www.wcrj.net\/article\/553 (accessed February 2020)."},{"key":"1365_CR21365","doi-asserted-by":"crossref","unstructured":"Arora A, Scholar E M. Role of Tyrosine Kinase Inhibitors in Cancer Therapy. J Pharmacol Exp Ther 2005; 315: 971-979.","DOI":"10.1124\/jpet.105.084145"},{"key":"1365_CR21368","unstructured":"National Cancer Institute. Targeted Cancer Therapies. 2018. Available at https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies\/targeted-therapies-fact-sheet (accessed October 2018)."},{"key":"1365_CR21371","unstructured":"Research Advocacy Network. Targeted Therapies in Cancer. 2013. Available at http:\/\/www.researchadvocacy.org\/sites\/default\/files\/resources\/TargetedTherapiesTutorial-Final.pdf (accessed October 2018)."},{"key":"1365_CR21373","unstructured":"Office for National Statistics. Overview of the UK population: August 2019. 2019. Available at https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/articles\/overviewoftheukpopulation\/august2019 (accessed October 2019)."},{"key":"1365_CR21375","unstructured":"Cancer Research UK. Cancer diagnosis and treatment. Available at https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/diagnosisandtreatment#heading-Three (accessed October 2019)."},{"key":"1365_CR21378","doi-asserted-by":"crossref","unstructured":"Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13: 209-227.","DOI":"10.1038\/nrclinonc.2015.213"},{"key":"1365_CR21380","unstructured":"Coulson A, Levy A, Gossell-Williams M. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. West Indian Med J 2014; 63: 650-654."},{"key":"1365_CR21382","unstructured":"American Cancer Society. Monoclonal antibodies and their side effects. Available at https:\/\/www.cancer.org\/treatment\/treatmentsandside-effects\/treatment-types\/immunotherapy\/monoclonal-antibodies.html (accessed May 2018)."},{"key":"1365_CR21385","unstructured":"World Health Organisation. Revised monoclonal antibody (mAb) nomenclature scheme. 2017. Available at: http:\/\/www.who.int\/medicines\/services\/inn\/Revised_mAb_nomenclature_scheme.pdf (accessed May 2018)."},{"key":"1365_CR21387","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 2014; 72: 1938-1956.","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"1365_CR21389","doi-asserted-by":"crossref","unstructured":"You Tm, Lee K H, Lee S H, Park W. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 548-553.","DOI":"10.1016\/j.oooo.2015.07.017"},{"key":"1365_CR21391","doi-asserted-by":"crossref","unstructured":"Malan J, Ettinger K, Naumann E, Beirne O R. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 671-676.","DOI":"10.1016\/j.oooo.2012.08.439"},{"key":"1365_CR21393","doi-asserted-by":"crossref","unstructured":"Zhang X, Hamadeh I S, Song S et al. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). J Bone Miner Res 2016; 31: 336-340.","DOI":"10.1002\/jbmr.2693"},{"key":"1365_CR21395","doi-asserted-by":"crossref","unstructured":"Estilo C L, Fornier M, Farooki A, Carlson D, Bohle G, Huryn J M. Osteonecrosis of the Jaw Related to Bevacizumab. J Clin Oncol 2008; 26: 4037-4038.","DOI":"10.1200\/JCO.2007.15.5424"},{"key":"1365_CR21398","doi-asserted-by":"crossref","unstructured":"Erovigni F, Gambino A, Cabras M et al. Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. Dent J (Basel) 2016; 4: 39.","DOI":"10.3390\/dj4040039"},{"key":"1365_CR21400","doi-asserted-by":"crossref","unstructured":"Guarneri V, Miles D, Robert N et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188.","DOI":"10.1007\/s10549-010-0866-3"},{"key":"1365_CR21402","doi-asserted-by":"crossref","unstructured":"Weigert K L, Lewgoy J, Mazzoleni D S, Franco F R, Enriconi L, Henrique Sasso J. Rituximab and Osteonecrosis of the Jaws: Case Study. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; DOI: 10.1016\/j.oooo.2013.12.203.","DOI":"10.1016\/j.oooo.2013.12.203"},{"key":"1365_CR21404","doi-asserted-by":"crossref","unstructured":"Allegra A, Oteri G, Alonci A et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg 2014; 42: 279-282.","DOI":"10.1016\/j.jcms.2013.05.014"},{"key":"1365_CR21407","doi-asserted-by":"crossref","unstructured":"Kerbin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. J Oral Maxillofac Surg 2017; 75: 2599-2605.","DOI":"10.1016\/j.joms.2017.05.016"},{"key":"1365_CR21410","doi-asserted-by":"crossref","unstructured":"Cassoni A, Romeo U, Terenzi V et al. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? Case Rep Dent 2016; DOI: 10.1155\/2016\/2856926.","DOI":"10.1155\/2016\/2856926"},{"key":"1365_CR21412","doi-asserted-by":"crossref","unstructured":"Favia G, Tempesta A, Limongelli L et al. A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. Am J Case Rep 2017; 18: 1351-1356.","DOI":"10.12659\/AJCR.905355"},{"key":"1365_CR21414","doi-asserted-by":"crossref","unstructured":"Cosman F, Crittenden D B, Adachi J D et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375: 1532-1543.","DOI":"10.1056\/NEJMoa1607948"},{"key":"1365_CR21416","doi-asserted-by":"crossref","unstructured":"Saag K G, Peterson J, Luisa Brandi M et al. Romosozumab or Alendronate for.Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377: 1417-1427.","DOI":"10.1056\/NEJMoa1708322"},{"key":"1365_CR21418","unstructured":"National Cancer Institute. Angiogenesis Inhibitors. 2018. Available at https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/angiogenesis-inhibitors-fact-sheet (accessed May 2018)."},{"key":"1365_CR21420","doi-asserted-by":"crossref","unstructured":"Riggs P, La Vallie E R, McCoy J M. Introduction to expression by fusion protein vectors. Curr Protoc Mol Biol 2001; DOI: 10.1002\/0471142727.mb1604as28.","DOI":"10.1002\/0471142727.mb1604as28"},{"key":"1365_CR21423","unstructured":"NICE. AFLIBERCEPT. Available at https:\/\/bnf.nice.org.uk\/drug\/aflibercept.html (accessed May 2018)."},{"key":"1365_CR21425","doi-asserted-by":"crossref","unstructured":"Tabernero J, Van Cutsem E, Lakom\u00fd R et al. Aflibercept Versus Placebo in Combination With Irinotecan and 5FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR). Eur J Cancer 2014; 50: 320-331.","DOI":"10.1016\/j.ejca.2013.09.013"},{"key":"1365_CR21427","doi-asserted-by":"crossref","unstructured":"Schmidt SR. Fusion proteins: Applications and Challenges. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges. 2013;  pp 3. Hoboken, NJ: Wiley-Blackwell.","DOI":"10.1002\/9781118354599"},{"key":"1365_CR21430","doi-asserted-by":"crossref","unstructured":"Mawardi H, Enzinger P, McCleary N et al. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 2016; 7: 81-87.","DOI":"10.21037\/jgo.2016.05.07"},{"key":"1365_CR21432","unstructured":"Medicines and Healthcare Products Regulatory Agency. Aflibercept (Zaltrap): minimising the risk of osteonecrosis of the jaw. 2016. Available at https:\/\/www.gov.uk\/drug-safety-update\/aflibercept-zaltrap-minimising-the-risk-of-osteonecrosis-of-the-jaw (accessed May 2018)."},{"key":"1365_CR21434","doi-asserted-by":"crossref","unstructured":"Ponzetti A, Pinta F, Spadi R et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016; DOI: 10.5301\/tj.5000405.","DOI":"10.5301\/tj.5000405"},{"key":"1365_CR21437","doi-asserted-by":"crossref","unstructured":"Zarringhalam P, Brizman E, Shakib K. Medication-related osteonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg 2017; 55: 314-315.","DOI":"10.1016\/j.bjoms.2016.11.315"},{"key":"1365_CR21439","unstructured":"Paul M K, Mukhopadhy A K. Tyrosine kinaserole and significance in cancer. Int J Med Sci 2004; 1: 101-115."},{"key":"1365_CR21441","doi-asserted-by":"crossref","unstructured":"Hartmann J T, Haap M, Kopp H G, Lipp H P. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 480-481.","DOI":"10.2174\/138920009788897975"},{"key":"1365_CR21443","doi-asserted-by":"crossref","unstructured":"Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13: 209-227.","DOI":"10.1038\/nrclinonc.2015.213"},{"key":"1365_CR21445","unstructured":"NICE. Evidence Search. Tyrosine kinase inhibitor. Available at https:\/\/www.evidence.nhs.uk\/search?q=Tyrosine+kinase+inhibitor (accessed May 2018)."},{"key":"1365_CR21448","doi-asserted-by":"crossref","unstructured":"Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 2017; 43: 120-124.","DOI":"10.5125\/jkaoms.2017.43.2.120"},{"key":"1365_CR21450","unstructured":"Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib - A case report with clinical implications. Forum Clin Oncol. 2013; 4: 29-33."},{"key":"1365_CR21453","doi-asserted-by":"crossref","unstructured":"Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F. Regorafenib Also Can Cause Osteonecrosis of the Jaw. J Natl Cancer Inst 2016; DOI: 10.1093\/jnci\/djw002.","DOI":"10.1093\/jnci\/djw002"},{"key":"1365_CR21455","doi-asserted-by":"crossref","unstructured":"Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J 2015; 60: 528-531.","DOI":"10.1111\/adj.12254"},{"key":"1365_CR21457","doi-asserted-by":"crossref","unstructured":"Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-164.","DOI":"10.1016\/S0014-5793(00)01520-9"},{"key":"1365_CR21460","doi-asserted-by":"crossref","unstructured":"Allen M R, Burr D B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67: 61-70.","DOI":"10.1016\/j.joms.2009.01.007"},{"key":"1365_CR21463","doi-asserted-by":"crossref","unstructured":"Xie J, Wang X, Proud C G. mTOR inhibitors in cancer therapy. F1000Res 2016; DOI: 10.12688\/f1000research.9207.1.","DOI":"10.12688\/f1000research.9207.1"},{"key":"1365_CR21465","unstructured":"Zheng Y, Jiang Y. mTOR Inhibitors at a Glance. Mol Cell Pharmacol 2015; 7: 15-20."},{"key":"1365_CR21467","doi-asserted-by":"crossref","unstructured":"Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. Br Dent J 2015; 219: 203-207.","DOI":"10.1038\/sj.bdj.2015.680"},{"key":"1365_CR21469","unstructured":"NICE. EVEROLIMUS. Available at https:\/\/bnf.nice.org.uk\/drug\/everolimus.html (accessed May 2018)."},{"key":"1365_CR21471","unstructured":"NICE. TEMSIROLIMUS. Available at https:\/\/bnf.nice.org.uk\/drug\/temsirolimus.html (accessed May 2018)"},{"key":"1365_CR21474","unstructured":"NICE. SIROLIMUS. Available at https:\/\/bnf.nice.org.uk\/drug\/sirolimus.html (accessed May 2018)."},{"key":"1365_CR21477","unstructured":"NICE. TACROLIMUS. Available at https:\/\/bnf.nice.org.uk\/drug\/tacrolimus.html (accessed May 2018)."},{"key":"1365_CR21479","doi-asserted-by":"crossref","unstructured":"Dancey J W, Monzon J. Ridaforolimus: a promising drug in the treatment of soft tissue sarcoma and other malignancies. Future Oncol 2011; 7: 827-839.","DOI":"10.2217\/fon.11.57"},{"key":"1365_CR21481","doi-asserted-by":"crossref","unstructured":"Kneissel M, Luong-Nguyen N H, Baptist M et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004; 35: 1144-1156.","DOI":"10.1016\/j.bone.2004.07.013"},{"key":"1365_CR21483","unstructured":"Lee C Y S, Lee K L, Hirata K Y, Suzuki J B. Medication-related osteonecrosis of the jaw with the mTOR inhibitor Everolimus in a patient with oestrogen-receptor positivie breast cancer: a case report. International J Oral Dent Health 2016; 2: 1-5."},{"key":"1365_CR21486","doi-asserted-by":"crossref","unstructured":"Yamamoto D, Tsubota Y, Utsunomiya T et al. Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol 2017; 6: 255-257.","DOI":"10.3892\/mco.2016.1100"},{"key":"1365_CR21488","unstructured":"Giancola F, Campisi G, Lo Russo L, Muzio L L, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: A unique case report? Ann Stomatol (Roma) 2013; 4: 20-21."},{"key":"1365_CR21490","doi-asserted-by":"crossref","unstructured":"Kim D W, Jung Y S, Park H S, Jung H D. Osteonecrosis of the jaw related to everolimus: A case report. Br J Oral Maxillofac Surg 2013; 51: 302-304.","DOI":"10.1016\/j.bjoms.2013.09.008"},{"key":"1365_CR21492","unstructured":"National Institute of Dental and Craniofacial Research. Dental Management of the Organ Transplant Patient. 2008. Available at https:\/\/www.in.gov\/isdh\/files\/OrganTransplantProf.pdf (accessed October 2019)."},{"key":"1365_CR21494","doi-asserted-by":"crossref","unstructured":"Ceccaci E, Minucci S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer. 2016; 114: 605-611.","DOI":"10.1038\/bjc.2016.36"},{"key":"1365_CR21497","doi-asserted-by":"crossref","unstructured":"Halsall J A, Turner B M. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success. Bioessays 2016; 38: 1102-1110.","DOI":"10.1002\/bies.201600070"},{"key":"1365_CR21500","doi-asserted-by":"crossref","unstructured":"Subramanian S, Bates S E, Wright J J, Espinoza-Delgado I, Piekarz R L. Clinical Toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel) 2010; 3: 2751-2767.","DOI":"10.3390\/ph3092751"},{"key":"1365_CR21502","doi-asserted-by":"crossref","unstructured":"Wang X, Ding J, Meng L. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmal Sin 2015; 36: 1170-1176.","DOI":"10.1038\/aps.2015.71"},{"key":"1365_CR21504","doi-asserted-by":"crossref","unstructured":"Fruman D A, Rommel C. PI3K and Cancer: Lessons, Challenges and Opportunities. Nat Rev Drug Discov 2014; 13: 140-156.","DOI":"10.1038\/nrd4204"},{"key":"1365_CR21506","unstructured":"NICE. IDELALISIB. Available at https:\/\/bnf.nice.org.uk\/drug\/idelalisib.html (accessed October 2019)."},{"key":"1365_CR21508","doi-asserted-by":"crossref","unstructured":"Crawford L J, Walker B, Irvine A E. Proteasome inhibitors in cancer therapy. J Cell Commun 2011; 5: 101-110.","DOI":"10.1007\/s12079-011-0121-7"},{"key":"1365_CR21511","doi-asserted-by":"crossref","unstructured":"Shinohara K, Tomoika M, Nakano H, Tone S, Ito H, Kawahima S. Apoptosis induction resulting from proteasome inhibition. Biochem J 1996; 317: 385-388.","DOI":"10.1042\/bj3170385"},{"key":"1365_CR21513","doi-asserted-by":"crossref","unstructured":"McConkey D J, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164-179.","DOI":"10.1016\/j.drup.2008.08.002"},{"key":"1365_CR21515","unstructured":"Nawrocki S T, Bruns C J, Harbison M T et al. Effects of the proteasome inhibitor PS341 on apoptosis and angiogenesis in orthotopic human pancreatic tumour xenografts. Mol Cancer Ther 2002; 1: 1243-1253."},{"key":"1365_CR21517","doi-asserted-by":"crossref","unstructured":"Kane R C, Farell A T, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12: 2955-2960.","DOI":"10.1158\/1078-0432.CCR-06-0170"},{"key":"1365_CR21520","unstructured":"NICE. CARFILZOMIB. Available at https:\/\/bnf.nice.org.uk\/drug\/carfilzomib.html (accessed October 2019)."},{"key":"1365_CR21523","unstructured":"NICE. IXAZOMIB. Available at https:\/\/bnf.nice.org.uk\/drug\/ixazomib.html (accessed October 2019)."},{"key":"1365_CR21525","doi-asserted-by":"crossref","unstructured":"Nagao H, Ijiri K, Hirotsu M et al. Role of GLI2 in the growth of human osteosarcoma. J Pathol 2011; 224: 169-179.","DOI":"10.1002\/path.2880"},{"key":"1365_CR21527","doi-asserted-by":"crossref","unstructured":"Ng J M, Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.","DOI":"10.1038\/nrc3079"},{"key":"1365_CR21529","doi-asserted-by":"crossref","unstructured":"Gorlin R J, Goltz R W. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. N Engl J Med 1960; 262: 908-912.","DOI":"10.1056\/NEJM196005052621803"},{"key":"1365_CR21531","doi-asserted-by":"crossref","unstructured":"Jain S, Song R, Xie J. Sonidegib: mechanism of action, pharmacology and clinical utility for advanced basal cell carcinomas. Onco Targets Ther 2017; 10: 1645-1653.","DOI":"10.2147\/OTT.S130910"},{"key":"1365_CR21533","doi-asserted-by":"crossref","unstructured":"Sekulic A, Migden M R, Oro A E et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.","DOI":"10.1056\/NEJMoa1113713"},{"key":"1365_CR21536","doi-asserted-by":"crossref","unstructured":"Rimkus T K, Carpenter R L, Qasem S, Chan M, Lo H W. Targeting the Sonic Hedgehog Signalling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) 2016; 8: 1-23.","DOI":"10.3390\/cancers8020022"},{"key":"1365_CR21538","doi-asserted-by":"crossref","unstructured":"Kumar R M R, Fuchs B. Hedgehog Signalling Inhibitors as Anti-Cancer Agents in Osteosarcoma. Cancers (Basel) 2015; 7: 784-794.","DOI":"10.3390\/cancers7020784"},{"key":"1365_CR21540","unstructured":"U.S. Department of Health and Human Services. Dental Provider's Pocket Oncology Guide. 2009. Available at https:\/\/www.nidcr.nih.gov\/sites\/default\/files\/2017-09\/oncology-guide-dental-provider_0.pdf (accessed February 2020)."},{"key":"1365_CR21542","doi-asserted-by":"crossref","unstructured":"Lopez B C, Esteve C G, Perez M G S. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent 2011; 3: 31-42.","DOI":"10.4317\/jced.3.e31"},{"key":"1365_CR21545","unstructured":"Cancer Research UK. Infection during or after treatment. 2019. Available at https:\/\/www.cancerresearchuk.org\/about-cancer\/coping\/physically\/fever\/causes\/infection\/during-or-after-treatment (accessed November 2019)."},{"key":"1365_CR21547","unstructured":"Chemocare: Nadir. Available at http:\/\/chemocare.com\/chemotherapy\/what-is-chemotherapy\/what-is-nadir.aspx (accessed November 2019)."},{"key":"1365_CR21550","doi-asserted-by":"crossref","unstructured":"King R, Tanna N, Patel V. Medication related osteonecrosis of the jaw unrelated to bisphosphonates and denosumaba review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127: 289-299.","DOI":"10.1016\/j.oooo.2018.11.012"},{"key":"1365_CR21552","doi-asserted-by":"crossref","unstructured":"Patel V, Mansi J, Ghosh S et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 2018; 224: 74-79.","DOI":"10.1038\/sj.bdj.2017.1039"},{"key":"1365_CR21554","unstructured":"The Royal College of Surgeons of England. The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and\/or Bone Marrow Transplantation: Clinical Guidelines. 2018. Available online at https:\/\/www.rcseng.ac.uk\/-\/media\/files\/rcs\/fds\/publications\/rcs-oncology-guideline-update--v36.pdf (accessed February 2020)."},{"key":"1365_CR21556","unstructured":"Medicines and Healthcare Products Regulatory Agency. Denosumab: updated recommendations. 2014. Available at https:\/\/www.gov.uk\/drugsafetyupdate\/denosumabupdatedrecommendations (accessed January 2020)."},{"key":"1365_CR21558","unstructured":"Medicines and Healthcare Products Regulatory Agency. Becavizumab and sunitinib: risk of osteonecrosis of the jaw. 2014. Available at https:\/\/www.gov.uk\/drugsafetyupdate\/bevacizumabandsunitinibriskofosteonecrosisofthejaw (accessed January 2020)."},{"key":"1365_CR21560","doi-asserted-by":"crossref","unstructured":"Schuurhuis J M, Span L F, Stokman M A, van Winkelhoff A J, Vissink A, Spijkervet F K. Effect of leaving chronic oral foci untreated on infectious complications during intensive chemotherapy. Br J Cancer 2016; 114: 972-978.","DOI":"10.1038\/bjc.2016.60"},{"key":"1365_CR21563","doi-asserted-by":"crossref","unstructured":"Vozza I, Caldarazzo V, Polimeni A, Ottolenghi L. Periodontal disease and cancer patients undergoing chemotherapy. Int Dent J 2015; 65: 45-48.","DOI":"10.1111\/idj.12133"},{"key":"1365_CR21566","doi-asserted-by":"crossref","unstructured":"Decker A M, Taichman L S, D'Silva N J, Taichman R S. Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 2018 Mar; 5: 7-12.","DOI":"10.1007\/s40496-018-0164-4"},{"key":"1365_CR21569","doi-asserted-by":"crossref","unstructured":"Harding J. Dental care of cancer patients before, during and after treatment. Br Dent J Team 2017; DOI: 10.1038\/bdjteam.2017.8.","DOI":"10.1038\/bdjteam.2017.8"},{"key":"1365_CR21571","doi-asserted-by":"crossref","unstructured":"Radfar L, Admadabadi R E, Masood F, Scofield R H. Biological Therapy and Dentistry: A review paper. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 594-601.","DOI":"10.1016\/j.oooo.2015.07.032"},{"key":"1365_CR21573","doi-asserted-by":"crossref","unstructured":"Newsome P N, Cramb R, Davison S M et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67: 6-19.","DOI":"10.1136\/gutjnl-2017-314924"},{"key":"1365_CR21576","doi-asserted-by":"crossref","unstructured":"Georgakopoulou E A, Scully C. Orofacial adverse effects of biological agents. J Investig Clin Dent 2014;DOI: 10.1111\/jicd.12102.","DOI":"10.1111\/jicd.12102"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41415-020-1365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41415-020-1365-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41415-020-1365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:37Z","timestamp":1684618717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-020-1365-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1038\/s41415-020-1365-5","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"27 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest from any of the authors listed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}